This company listing is no longer active
DSM-Firmenich Past Earnings Performance
Past criteria checks 1/6
DSM-Firmenich's earnings have been declining at an average annual rate of -20.7%, while the Chemicals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 0.8% per year. DSM-Firmenich's return on equity is 4.4%, and it has net margins of 5.4%.
Key information
-20.7%
Earnings growth rate
-20.2%
EPS growth rate
| Chemicals Industry Growth | 12.4% |
| Revenue growth rate | -0.8% |
| Return on equity | 4.4% |
| Net Margin | 5.4% |
| Next Earnings Update | 02 Aug 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How DSM-Firmenich makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|
Quality Earnings: DSM2 has high quality earnings.
Growing Profit Margin: DSM2's current net profit margins (5.4%) are lower than last year (11.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DSM2's earnings have declined by 20.7% per year over the past 5 years.
Accelerating Growth: DSM2's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DSM2 had negative earnings growth (-44.6%) over the past year, making it difficult to compare to the Chemicals industry average (-12.3%).
Return on Equity
High ROE: DSM2's Return on Equity (4.4%) is considered low.